Editor's note

This article was originally published on 5 March 2015 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

Industry overview

VacZine Analytics estimates that the top vaccine players generated approximately $22 billion in combined vaccine revenues in 2014. The headline figure masks significant structural change: the year saw the formal close of the GSK-Novartis vaccine asset exchange, which transferred Bexsero®, Menveo® and other Novartis vaccine products to GSK's portfolio. This transaction fundamentally repositioned GSK as the dominant player across the meningococcal franchise.

Industry Total 2014
~$22bn

Estimated combined vaccine revenues for the top global vaccine players in 2014

Sanofi: influenza franchise +25%

Sanofi Pasteur delivered strong influenza performance, with the franchise growing approximately 25% driven by continued uptake of differentiated products including Fluzone High-Dose (HD) in the elderly segment and expanded quadrivalent (QIV) distribution. The company estimated that one in three elderly Americans could receive Fluzone HD in the 2014-15 season, with preliminary calculations suggesting blockbuster potential if penetration continued to grow.

Merck: $5.7bn in vaccine revenues

Merck & Co reported approximately $5.7 billion in vaccine revenues for 2014, with Gardasil, Zostavax and Pneumovax all recording solid performance. Gardasil-9, approved by the FDA in December 2014, positioned the company for the next phase of its HPV lifecycle management strategy.

Pfizer: TRUMENBA approved, C. diff on hold

Pfizer's Prevnar/Prevenar-13 franchise recorded approximately $4,480 million in 2014. On the pipeline front, the company received FDA approval for its meningococcal serogroup B vaccine TRUMENBA® (bivalent rLP2086) for 10-25 year olds - making it the second MenB vaccine licensed in the US alongside GSK's Bexsero®. However, in a setback, Pfizer announced it was putting its Clostridium difficile vaccine programme on hold pending review of Phase II data, a disappointment given the significant unmet medical need in the nosocomial infection space.

"The close of the GSK-Novartis vaccine transaction in 2014 created a new dominant force in meningococcal vaccines with no immediate parallel."

Outlook

The industry enters 2015 with its structure materially altered by M&A activity. New product launches including dengue, MenB programmes and next-generation influenza vaccines provide incremental growth opportunities. However, the next step-change in industry revenues will require successful execution of more transformative programmes - malaria, RSV and broadly protective influenza vaccines among them.